351 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009

伦瓦提尼 彭布罗利珠单抗 医学 肿瘤科 免疫疗法 头颈部鳞状细胞癌 化疗 内科学 头颈部癌 头颈部 放射治疗 外科 癌症 甲状腺癌
作者
Kevin J. Harrington,Ezra E.W. Cohen,L.L. Siu,Danny Rischin,Lisa Licitra,Jan B. Vermorken,Quynh‐Thu Le,Makoto Tahara,Jean‐Pascal Machiels,Natalyn Hawk,Joy Yang Ge,Behzad Bidadi,Ramona F. Swaby,Barbara Burtness
出处
期刊: 卷期号:: A214.1-A214 被引量:2
标识
DOI:10.1136/jitc-2020-sitc2020.0351
摘要

Background

Pembrolizumab alone and in combination with platinum-based chemotherapy have become standard first-line treatment options for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), and there is a growing unmet need for safe and efficacious treatment options for R/M HNSCC that has progressed on or after platinum-based chemotherapy and immunotherapy. Data from Study 111/KEYNOTE-146 showed promising antitumor activity and acceptable safety for the PD-1 inhibitor pembrolizumab given in combination with the multikinase inhibitor lenvatinib in patients with metastatic HNSCC.1 LEAP-009 (NCT04428151), a global, randomized, open-label, phase 2 trial, will assess the efficacy and safety of pembrolizumab in combination with lenvatinib versus SOC chemotherapy, as well as the efficacy and safety of lenvatinib monotherapy, in patients with R/M HNSCC that has progressed after platinum-based chemotherapy and a PD-(L)1 inhibitor.

Methods

Eligible patients are adults with histologically confirmed, locally incurable R/M HNSCC of the oral cavity, oropharynx, hypopharynx, or larynx, disease progression at any time during or after platinum-containing chemotherapy (with or without cetuximab), disease progression within 12 weeks from the last dose of treatment with ≥2 doses of a PD-(L)1 inhibitor, measurable disease based on RECIST v1.1 as confirmed by BICR, ECOG performance status of 0 or 1, and no major blood vessel invasion/infiltration. Patients will be randomized 3:3:2 to pembrolizumab (200 mg IV Q3W for up to 35 cycles) plus lenvatinib (20 mg orally once daily), investigator's choice of SOC chemotherapy (docetaxel, paclitaxel, cetuximab, or capecitabine), or lenvatinib monotherapy (24 mg orally once daily). Randomization will be stratified by PD-L1 tumor proportion score (<50% versus ≥50%) and ECOG performance status (0 versus 1). Treatment will continue until centrally verified disease progression, unacceptable toxicity, or decision to withdraw. Patients in the chemotherapy and lenvatinib monotherapy arms may be eligible to receive pembrolizumab plus lenvatinib upon disease progression. The primary endpoint is ORR according to modified RECIST v1.1 as assessed by BICR. Secondary endpoints include PFS, OS, DOR, and safety. Interim futility analysis will be conducted for the lenvatinib monotherapy arm. Tumor imaging by CT or MRI will be performed 6 weeks after randomization, every 6 weeks through year 1, and every 9 weeks thereafter. Safety will be monitored throughout the study and for 30 days after treatment end (90 days for serious AEs if no new anticancer treatment is initiated, and at any time if the AE is considered treatment-related). Recruitment is ongoing; Planned enrollment is ~400 patients.

Results

N/A

Conclusions

N/A

Trial Registration

ClinicalTrials. gov Identifier, NCT04428151

Ethics Approval

The study and protocol were approved by the Institutional Review Board or ethics committee at each site.

Consent

All patients provided written informed consent to participate in the clinical trial.

Reference

Matthew H Taylor, Chung-Han Lee, Vicky Makker, et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol 2020;38(11):1154–1163.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wang完成签到,获得积分10
刚刚
刚刚
范范发布了新的文献求助10
1秒前
Henry完成签到,获得积分10
1秒前
Frain完成签到,获得积分10
1秒前
1秒前
WQQ完成签到,获得积分10
2秒前
Jing发布了新的文献求助10
2秒前
LIFE完成签到,获得积分20
2秒前
2秒前
awwwww完成签到,获得积分10
2秒前
3秒前
TIANJINGRUN发布了新的文献求助10
3秒前
Eric完成签到,获得积分10
3秒前
3秒前
chendahuanhuan完成签到,获得积分10
3秒前
lhcshuang发布了新的文献求助10
4秒前
xiaofeng完成签到,获得积分10
4秒前
4秒前
史玉英完成签到,获得积分10
4秒前
4秒前
4秒前
小蘑菇的应助被快乐十一采纳,获得20
5秒前
丘比特的应助被dadadaniu采纳,获得10
5秒前
behemoth完成签到 ,获得积分10
5秒前
5秒前
456完成签到,获得积分10
5秒前
xin发布了新的文献求助10
5秒前
6秒前
勇敢牛牛完成签到 ,获得积分10
6秒前
lemongulf完成签到,获得积分10
6秒前
可爱的函函的应助被wuming7890采纳,获得10
7秒前
三斤完成签到 ,获得积分10
7秒前
乐小子完成签到,获得积分10
7秒前
范范完成签到,获得积分20
7秒前
曼冬完成签到,获得积分10
8秒前
hhud发布了新的文献求助10
8秒前
8秒前
风吹麦浪的应助被JOJO采纳,获得10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153299
求助须知:如何正确求助?哪些是违规求助? 9549963
关于积分的说明 21695977
捐赠科研通 7741796
什么是DOI,文献DOI怎么找? 3425434
关于科研通互助平台的介绍 2550601
邀请新用户注册赠送积分活动 2469116